Compare AANJANEYA LIFECARE with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS AUROBINDO PHARMA DR. DATSONS LABS/
AUROBINDO PHARMA
 
P/E (TTM) x -10.9 16.8 - View Chart
P/BV x 0.2 3.6 4.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 DR. DATSONS LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
AUROBINDO PHARMA
Mar-19
DR. DATSONS LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126830 15.1%   
Low Rs31527 5.9%   
Sales per share (Unadj.) Rs133.0333.9 39.8%  
Earnings per share (Unadj.) Rs0.240.4 0.4%  
Cash flow per share (Unadj.) Rs6.651.8 12.8%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs128.8237.1 54.3%  
Shares outstanding (eoy) m31.66585.91 5.4%   
Bonus/Rights/Conversions FCCBESOP-  
Price / Sales ratio x0.62.0 29.0%   
Avg P/E ratio x516.116.8 3,069.6%  
P/CF ratio (eoy) x11.813.1 90.3%  
Price / Book Value ratio x0.62.9 21.2%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m2,477397,569 0.6%   
No. of employees `000NA17.9 0.0%   
Total wages/salary Rs m5625,849 0.2%   
Avg. sales/employee Rs ThNM10,956.9-  
Avg. wages/employee Rs ThNM1,447.7-  
Avg. net profit/employee Rs ThNM1,324.3-  
INCOME DATA
Net Sales Rs m4,211195,636 2.2%  
Other income Rs m791,553 5.1%   
Total revenues Rs m4,289197,189 2.2%   
Gross profit Rs m56939,519 1.4%  
Depreciation Rs m2046,680 3.1%   
Interest Rs m4302,626 16.4%   
Profit before tax Rs m1331,767 0.0%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m67,269 0.1%   
Profit after tax Rs m523,645 0.0%  
Gross profit margin %13.520.2 66.9%  
Effective tax rate %48.022.9 209.9%   
Net profit margin %0.112.1 0.9%  
BALANCE SHEET DATA
Current assets Rs m6,852153,645 4.5%   
Current liabilities Rs m6,711120,429 5.6%   
Net working cap to sales %3.317.0 19.7%  
Current ratio x1.01.3 80.0%  
Inventory Days Days161135 119.0%  
Debtors Days Days31864 500.0%  
Net fixed assets Rs m3,673103,909 3.5%   
Share capital Rs m317586 54.0%   
"Free" reserves Rs m3,761138,322 2.7%   
Net worth Rs m4,078138,908 2.9%   
Long term debt Rs m1,6711,800 92.8%   
Total assets Rs m12,633264,544 4.8%  
Interest coverage x1.013.1 7.9%   
Debt to equity ratio x0.40 3,163.0%  
Sales to assets ratio x0.30.7 45.1%   
Return on assets %3.49.9 34.7%  
Return on equity %0.117.0 0.7%  
Return on capital %7.723.8 32.2%  
Exports to sales %22.949.6 46.1%   
Imports to sales %14.318.8 76.1%   
Exports (fob) Rs m96497,091 1.0%   
Imports (cif) Rs m60236,741 1.6%   
Fx inflow Rs m96497,316 1.0%   
Fx outflow Rs m60740,589 1.5%   
Net fx Rs m35756,727 0.6%   
CASH FLOW
From Operations Rs m1,34516,220 8.3%  
From Investments Rs m-2,256-28,768 7.8%  
From Financial Activity Rs m-1,20019,191 -6.3%  
Net Cashflow Rs m-2,1116,656 -31.7%  

Share Holding

Indian Promoters % 4.5 54.1 8.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.0 -  
FIIs % 1.4 27.7 4.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.2 922.5%  
Shareholders   20,807 69,601 29.9%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  ELDER PHARMA  

Compare DR. DATSONS LABS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

How Much Money For Day Trading?(Fast Profits Daily)

Feb 22, 2021

In this video, I'll show you how to allocate your capital as a day trader.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS